Literature DB >> 26194049

Second primary malignancies after radiotherapy including HDR (252)Cf brachytherapy for cervical cancer.

Vitalija Samerdokiene1, Konstantinas Povilas Valuckas2, Ernestas Janulionis2, Vydmantas Atkocius3, Mark J Rivard4.   

Abstract

PURPOSE: Second primary malignancies (SPMs) are among the most serious late adverse effects after radiotherapy experienced over time by the increasing population of cancer survivors worldwide. The study aim was to determine the rate and distribution of SPMs for neutron- and photon-emitting brachytherapy (BT) sources for patients treated for cervical cancer. METHODS AND MATERIALS: The cohort comprised 662 patients with invasive cervical cancer (Stages IIB and IIIB) and contributed 5,224 patient-years (PY) of observation. These patients were treated by radiotherapy during the 1989-1999 year period with cobalt-60 source ((60)Co) teletherapy. The first group of patients (N = 375; 3,154 PY) received high-dose-rate (HDR) californium-252 source ((252)Cf) BT, whereas the second group (N = 287; 2,070 PY) received HDR (60)Co BT.
RESULTS: Over a 25-year period, 35 SPMs were observed, amounting to 5.3% of all observed patients: in 16 (2.4%) heavily, 2 (0.3%) moderately, 14 (2.1%) lightly irradiated body sites, and 3 (0.5%) other sites. Of these, 21 cases (5.6%) were observed in the HDR (252)Cf BT group, whereas 14 cases (4.9%) were observed in the HDR (60)Co BT group. Exposures received during (60)Co teletherapy and HDR BT with either (252)Cf or (60)Co had statistically equivalent (p = 0.68) effects on SPM development.
CONCLUSIONS: Cure rates are improving, and therefore, there are more long-term survivors from cervical cancer. This study shows no significant difference in rates or distribution of SPMs in women treated with neutron BT compared with photon BT (p = 0.68). After reviewing related literature and our research results, it is evident that a detailed investigation of SPM frequency, localization, and dose to adjacent organs is a suitable topic for further research.
Copyright © 2015 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (252)Cf brachytherapy; Cervical cancer; Second primary malignancies

Mesh:

Substances:

Year:  2015        PMID: 26194049     DOI: 10.1016/j.brachy.2015.06.006

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  3 in total

1.  Californium versus cobalt brachytherapy combined with external-beam radiotherapy for IIB stage cervical cancer: long-term experience of a single institute.

Authors:  Ernestas Janulionis; Konstantinas Povilas Valuckas; Sarune Liukpetryte; Vitalija Samerdokiene; Vydmantas Atkocius
Journal:  J Contemp Brachytherapy       Date:  2015-10-19

2.  A retrospective study of californium-252 neutron brachytherapy combined with EBRT versus 3D-CRT in the treatment of esophageal squamous cell cancer.

Authors:  Qifeng Wang; Tao Li; Jinyi Lang; Jie Wang; Jian Wang; Huiming Liu; Xitang Jia; Bo Liu; C-K Chris Wang
Journal:  Radiat Oncol       Date:  2015-10-24       Impact factor: 3.481

3.  Leiomyosarcoma of the Rectum as a Radiation-Induced Second Malignancy after Cervical Cancer Treatment: Case Report with Review of the Literature.

Authors:  Dmytro E Makhmudov; Olena O Kolesnik; Natalia N Lagoda; Maryna O Volk
Journal:  Case Rep Oncol Med       Date:  2019-12-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.